Expanding Minimally Invasive Solutions for Women’s Health
Hologic (Nasdaq: HOLX) announced the completion of its $350 million acquisition of Gynesonics, a leader in minimally invasive women’s health solutions. The deal, initially disclosed in October, adds the Sonata system to Hologic’s portfolio.
Innovative Technology for Fibroid Treatment
Gynesonics’ Sonata system combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation, offering a completely incisionless treatment for symptomatic uterine fibroids, including those causing heavy menstrual bleeding.
Brandon Schnittker, President of Surgical Solutions at Hologic, highlighted the system’s potential:
“Sonata complements and expands our range of minimally invasive solutions, empowering surgeons and transforming women’s lives.”
Strategic Growth in Women’s Health
This marks Hologic’s second major acquisition in six months, following its $310 million purchase of Endomagnetics in July. With Endomagnetics’ wireless breast surgery solutions and Sonata’s fibroid treatment capabilities, Hologic continues to enhance its women’s health portfolio with cutting-edge technologies.
Commitment to Transformative Care
Hologic’s acquisition reinforces its dedication to providing innovative solutions that improve access to advanced care for women worldwide.
Stay updated with MEDWIRE.AI for the latest advancements shaping the future of healthcare.
